GSM9679560: Control Hepa1-6 tumor tissues; Mus musculus; RNA-Seq
CD147-LYTACs were administered intraperitoneally (or intravenously) at a dosage of 40 mg/kg every three days for a total of four doses. On day 12, tumor tissues were harvested, dissociated into single-cell suspensions, and subsequently sorted into CD45⁻ and CD45⁺ populations via flow cytometry. To ensure sufficient representation of the immune landscape, the sorted CD45⁻ and CD45⁺ cells were re-mixed at a defined ratio of 1:3 prior to single-cell RNA sequencing (scRNA-seq) profiling. Single-cell RNA-seq libraries were prepared using the 10x Genomics Chromium platform according to the manufacturer's protocols. Single-cell suspensions were loaded into the Chromium instrument to generate Gel Bead-in-Emulsions (GEMs) for cell barcoding and RNA reverse transcription. After library construction, the samples were sequenced on an Illumina NextSeq platform (Illumina, San Diego, CA, USA).